<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03267108</url>
  </required_header>
  <id_info>
    <org_study_id>PULSE-PHPF-001</org_study_id>
    <nct_id>NCT03267108</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of Pulsed Inhaled Nitric Oxide in Pulmonary Hypertension Associated With Pulmonary Fibrosis</brief_title>
  <official_title>Randomized, Double-Blind, Placebo-Controlled Dose Escalation and Verification Study to Assess the Safety and Efficacy of Pulsed iNO in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis on Long Term Oxygen Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bellerophon Pulse Technologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bellerophon</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bellerophon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, placebo-controlled dose escalation and verification study to
      assess the safety and efficacy of pulsed iNO versus placebo in subjects at risk for pulmonary
      hypertension associated with pulmonary fibrosis on long term oxygen therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase 3, randomized, double-blind, placebo-controlled dose escalation clinical study to
      assess the safety and efficacy of pulsed inhaled nitric oxide (iNO) versus placebo in
      subjects with pulmonary fibrosis on long term oxygen therapy.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 29, 2017</start_date>
  <completion_date type="Anticipated">March 23, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 16, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Moderate to Vigorous Physical Activity (MVPA) as Measured by Actigraphy</measure>
    <time_frame>Baseline of Blinded Treatment to Month 4</time_frame>
    <description>Part 1 - Blinded Treatment Period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events and Serious Adverse Events with Long Term Therapy will be Summarized</measure>
    <time_frame>Baseline of OLE to Month 4</time_frame>
    <description>Part 2 - Open Label Extension (OLE)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Overall Activity as Measured by Actigraphy</measure>
    <time_frame>Baseline of Blinded Treatment to Month 4</time_frame>
    <description>Part 1 - Blinded Treatment Period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in University of California San Diego (UCSD) Shortness of Breath Questionnaire (SOBQ)</measure>
    <time_frame>Baseline of Blinded Treatment to Month 4</time_frame>
    <description>Part 1 - Blinded Treatment Period: The UCSD SOBQ is a 24-item questionnaire developed to measure breathlessness associated with activities of daily living, on a scale between zero and five where 0 is not at all breathless and 5 is maximally breathless or too breathless to do the activity. The responses to all items are summed up to provide the overall score that can range from 0 (best outcome) to 120 (worst outcome).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in St. George Respiratory Questionnaire (SGRQ) - Activity, Impacts &amp; Total</measure>
    <time_frame>Baseline of Blinded Treatment to Month 4</time_frame>
    <description>Part 1 - Blinded Treatment Period: SGRQ is a tool for assessing quality of life that has previously been validated for the use with patients with interstitial lung disease. It is a responsive tool that has three domains: symptoms, activity and impact (on daily life)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Worsening - defined as first clinically adjudicated event of either death (all cause), Need for Hospitalization due to cardiopulmonary worsening, Reduction in 6 Minute Walk Distance (6MWD)</measure>
    <time_frame>Baseline of Blinded Treatment to Month 4</time_frame>
    <description>Part 1 - Blinded Treatment Period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Deterioration - defined as the 1st event observed at 2 sequential visits or at Month 4 of either St. George Respiratory Quest., U of Cal San Diego Shortness of Breath Quest., Six Minute Walk Distance, Moderate Vigorous Physical Activity</measure>
    <time_frame>Baseline of Blinded Treatment to Month 4</time_frame>
    <description>Part 1 - Blinded Treatment Period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Improvement - defined as the 1st event observed at 2 sequential visits or at Month 4 of either St. George Respiratory Quest., U of Cal San Diego Shortness of Breath Quest., Six Minute Walk Distance, Moderate Vigorous Physical Activity</measure>
    <time_frame>Baseline of Blinded Treatment to Month 4</time_frame>
    <description>Part 1 - Blinded Treatment Period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 6 Minute Walk Distance</measure>
    <time_frame>Baseline of Blinded Treatment to Month 4</time_frame>
    <description>Part 1 - Blinded Treatment Period</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Pulmonary Fibrosis</condition>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>Inhaled Nitric Oxide (iNO)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pulsed inhaled iNO45 mcg/kg Ideal Body Weight (IBW)/hour (hr)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Pulsed inhaled N2, 99.999% gas</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open Label Extension</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Open Label Therapy iNO45 mcg/kg IBW/hr</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>iNOpulse</intervention_name>
    <description>Subjects will be treated by means of an iNOpulse device using an iNOpulse nasal cannula.</description>
    <arm_group_label>Inhaled Nitric Oxide (iNO)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will be treated by means of an iNOpulse device using an iNOpulse nasal cannula.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Open Label Extension</intervention_name>
    <description>Subjects will be treated by means of an iNOpulse device using an iNOpulse nasal cannula.</description>
    <arm_group_label>Open Label Extension</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Part 1: Blinded Treatment Period

        Inclusion criteria: Subjects must meet all of the following inclusion criteria to be
        enrolled and eligible to participate in the study:

          1. Signed Informed Consent Form (and assent as appropriate) prior to the initiation of
             any study mandated procedures or assessments.

          2. Diagnosed with pulmonary fibrosis by high resolution CT scan performed in the 6 months
             prior to screening associated with one of the following conditions and confirmed using
             guidelines, as per American Thoracic Society (ATS) / European Respiratory Society
             (ERS) / Japanese Respiratory Society (JRS) / Latin American Thoracic Association
             (ALAT): Major IIPs (idiopathic interstitial pneumonias) diagnosis or suspected as one
             of the following:

               -  Idiopathic pulmonary fibrosis

               -  Idiopathic nonspecific interstitial pneumonia

               -  Respiratory bronchiolitis-interstitial lung disease

               -  Desquamative interstitial pneumonia

               -  Cryptogenic organizing pneumonia

               -  Acute interstitial pneumonia

             Rare IIPs diagnosis by one of the following:

               -  Idiopathic lymphoid interstitial pneumonia

               -  Idiopathic pleuroparenchymal fibroelastosis

             Unclassifiable idiopathic interstitial pneumonias

               -  Chronic hypersensitivity pneumonitis

               -  Occupational lung disease

          3. Low or Intermediate/high probability of pulmonary hypertension (PH) by echocardiogram
             as assessed by local

             Radiologist/Investigator, or PH as determined by a right heart catheterization (RHC)
             within 3 years prior to Baseline with the following parameters:

               1. Pulmonary vascular resistance (PVR) ≥ 3 Wood Units (WU) (320 dynes.sec.cm-5)

               2. A left ventricular end diastolic pressure (LVEDP) or pulmonary capillary wedge
                  pressure (PCWP) ≤ 15 mmHg

               3. A mean pulmonary arterial pressure (mPAP) of ≥ 21 mmHg

                    -  If a right heart catheterization is negative for PH within the past year,
                       subjects will be stratified to low probability of PH

          4. Have been using oxygen therapy by nasal cannula for at least 4 weeks prior to the
             screening run-in period.

          5. 6MWD ≥ 100 meters and ≤ 400 meters at screening and Baseline/Randomization visits.

          6. World Health Organization (WHO) Functional Class II-IV

          7. Forced Vital Capacity ≥ 40% predicted within last 6 months prior to screening the
             screening run-in period.

          8. Willingness to use INOpulse delivery device for at least 12 hours per day

          9. Female subjects of childbearing potential must have a negative pre-treatment pregnancy
             test (serum or urine). All female subjects should take adequate precaution to avoid
             pregnancy.

         10. Subjects must have completed at least 1 week of activity monitoring at time of the
             Baseline/Randomization visit.

         11. During the Screening Run-In period prior to Baseline/Randomization, subjects must
             demonstrate the ability to consistently use the INOpulse device greater than 12
             hrs/day in the opinion of the investigator.

         12. Age between 18 and 80 years (inclusive)

         13. Subject should be clinically stable for at least 4 weeks prior to
             Baseline/Randomization in the opinion of the Principal Investigator.

         14. During the Screening Run-In period, subjects must demonstrate their ability to wear
             the activity monitor for at least 10 hours per day when awake at the time of the
             Baseline/Randomization visit in the opinion of the investigator.

        Exclusion criteria: Subjects who meet any of the following criteria are not eligible for
        enrollment:

          1. Demonstrate symptomatic rebound defined as significant cardiopulmonary instability,
             such as systemic arterial oxygen desaturation, hypoxemia, bradycardia, tachycardia,
             systemic hypotension, shortness of breath, near-syncope, and syncope, occurring within
             1 hour of acute iNO during rebound testing

          2. Episodes of disease worsening within 1 month prior to Baseline/Randomization

          3. Use of prostacyclin, guanylate cyclase stimulators, or endothelin receptor antagonists
             (ERA) pulmonary arterial hypertension (PAH)-specific medications regardless of reason
             for use (use of Phosphodiesterase-5 (PDE-5)) inhibitors regardless of reason for use
             is allowed)

          4. Acute or chronic physical impairment (other than dyspnea due to PF) that would limit
             the ability to comply with study procedures or adherence to therapy (i.e., 6MWT),
             including carrying and wearing the pulsed delivery INOpulse device per study protocol,
             or medical problem(s) likely to preclude completion of the study

          5. Pregnant or breastfeeding females at Screening

          6. Administered L-arginine within 1 month prior to Screening

          7. The concurrent use of the INOpulse device with a continuous positive airway pressure
             (CPAP), Bilevel positive airway pressure (BPAP), or any other positive pressure
             device.

          8. Use of investigational drugs or devices within 1 month prior to Screening (other than
             acute vasodilator testing with iNO)

          9. Any underlying medical or psychiatric condition that, in the opinion of the
             Investigator, makes the subject an unsuitable candidate for the study including unable
             to complete 6MWT

         10. Any subject who has been enrolled in any previous clinical study with inhaled NO
             administered through pulse delivery

         11. A definitive diagnosis of a connective tissue disease (eg, systemic sclerosis via
             American College of Rheumatology/European League Against Rheumatism (ACR/EULAR)
             classification criteria)

         12. The presence of emphysema unless the extent of fibrotic changes is greater than the
             extent of emphysema on the most recent HRCT scan in the opinion of the local
             radiologist/Investigator.

         13. A subject should not start a rehabilitation program during the study, not have started
             within 3 months of screening or change the nature of their rehabilitation program at
             any time during the blinded portion of the study.

        Part 2: Open Label Period

        Inclusion Criteria: Subjects must meet all of the following inclusion criteria to be
        eligible to participate in Part 2 of the trial:

          1. All subjects must have completed Part 1- Blinded Treatment Period study assessments.

          2. In the opinion of the investigator, the subject would benefit from continued therapy
             with iNO 45. For Cohort 1 and 2 subjects, if investigator believes the subject's prior
             treatment dose of iNO 30 or iNO 75 mcg/kg IBW/hr is medically justified and would
             benefit the subject, agreement with the Sponsor's Medical Monitor should be obtained
             prior to enrollment.

        Exclusion Criteria:

          1. Use of prostacyclin, guanylate cyclase stimulator or ERA PAH-specific medications
             regardless of reason for use (use of PDE-5 inhibitors regardless of reason for use is
             allowed).

          2. The concurrent use of the INOpulse device with CPAP/BiPAP, or any other positive
             pressure device.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hunter Gillies, MD</last_name>
    <role>Study Director</role>
    <affiliation>Bellerophon Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Pulmonary Specialists, Ltd.</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>David Geffen School of Medicine at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Davis Health</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Denver Anschutz Medical Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avanza Medical Research Center</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Healthcare</name>
      <address>
        <city>Austell</city>
        <state>Georgia</state>
        <zip>30106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellstar Medical Group - Pulmonary Medicine</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kentuckiana Pulmonary Associates</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Lung Research Center, LLC</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of North Carolina at Chapel Hill Marsico Clinical Research Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27517</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Korman Respiratory Institute</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Health Sciences</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Heart and Vascular Institute Advanced Lung Disease Clinic</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonary Associates of Richmond</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>981195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 27, 2017</study_first_submitted>
  <study_first_submitted_qc>August 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2017</study_first_posted>
  <last_update_submitted>June 12, 2020</last_update_submitted>
  <last_update_submitted_qc>June 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary Fibrosis</keyword>
  <keyword>PF</keyword>
  <keyword>Pulmonary Hypertension</keyword>
  <keyword>Inhaled Nitric Oxide</keyword>
  <keyword>iNO</keyword>
  <keyword>Long Term Oxygen Therapy</keyword>
  <keyword>Oxygen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

